Acta Dermato-Venereologica 99-7CompleteContent | Page 21

SHORT COMMUNICATION 691 Evaluation of Sentinel Lymph Node Biopsy for Eccrine Porocarcinoma Kanako TSUNODA 1 *, Masazumi ONISHI 1 , Fumihiko MAEDA 1 , Toshihide AKASAKA 2 , Tamotsu SUGAI 3 and Hiroo AMANO 1 * Department of Dermatology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, 2 Department of Dermatology, Kitakami Saiseikai Hospital, Iwate, and 3 Department of Molecular Diagnostic Pathology, School of Medicine, Iwate Medical University, Morioka, Japan. E-mail: [email protected]; [email protected] 1 Accepted Mar 13, 2019; E-published Mar 14, 2019 Eccrine porocarcinoma (EPC) is a sweat gland carcinoma thought to arise from the lower portion of intraepidermal eccrine ducts. This tumour is rare (0.005–0.01% of all ma- lignant skin tumours) (1) and information about its biological behaviour is limited, although it is known to be aggressive. Previous studies have reported that the local recurrence rate is 17–20% (2), the regional lymph node (RLN) metastasis rate 20%, and the distant metastasis rate 11% (3). In patients who have RLN metastasis, the prognosis is poor, with a mortality rate of 65% (4). In EPC, the lymphogenous route is thought to be the main initial metastatic pathway, and therefore it can be reasonably expected that the prognosis would be improved by sentinel lymph node (SLN) biopsy, discovery of early lymph node metastasis, and RLN dissection. However, few case reports have documented the use of SLN biopsy in patients with EPC, and no large-scale studies have been conducted. Our department has been conducting SLN biopsy for EPC since 2009, and during this period we have accumulated 13 surgical cases of EPC. This paper reviews these cases, to- gether with previous reports of EPC, and discusses the use of SLN biopsy for this malignancy and future issues. PATIENTS, METHODS AND RESULTS Between 2009 and 2017, 13 patients were diagnosed as having EPC at the Department of Dermatology, Iwate Medical University, Iwate, Japan. Pathologically, the tumours showed malignant charac- teristics, such as irregular structures, invasive growth and unclear borders. They consisted of atypical poroid cells with dark basaloid staining and cuticular cells with eosinophilic staining. Duct struc- tures were also evident. The tumour cells were immunopositive for carcinoembryonic antigen (CEA) and/or epithelial membrane anti- gen (EMA). SLN biopsy was performed for cases in which lymph node/distant metastasis was not recognized by imaging (computed tomography (CT) and/or positron emission tomography – computed tomography (PET – CT)) before surgery. On the other hand, SLN biopsy was not performed for cases in which metastasis to RLN was clear or obvious based on preoperative imaging examination; instead, immediate RLN dissection was performed in all such cases. For identification of SLN, the radioisotope (RI) method and indocyanine green (ICG) fluorescence method were used together. A detailed description of the SLN is shown in Appendix S1 1 . Among the 13 cases, only one was treated by simple wide resection of the primary tumour. The patient was elderly and did not wish to undergo SLN biopsy, opting for minimally invasive surgery. Clinical and imaging findings before surgery demonstrated no lymph node metastasis, and SLN biopsy was performed in 8 cases. Among them, 3 cases were positive for SLN metastasis (positivity rate 37.5%). In 4 cases where clinical and/or imaging examinations revealed RLN metastasis, dissection of the affected https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3173 1 nodes was performed at initial surgery (Fig. S1 1 ). The characte- ristics of each treatment group are shown in Table SI 1 . The clini- copathological features of SLN biopsy metastasis-negative cases are shown in Table SII 1 and those of positive cases in Table SIII 1 . RLN dissection was performed in all 3 patients who were positive for SLN metastasis. The mean observation period was 28.7 months and, at time of writing, all of the 3 patients are currently alive. In one patient (Case 1 in Table SIII 1 ), recurrence was observed in the parotid gland at 22 months, and resection was performed. The mean Ki-67 labelling index in the SLN metastasis-negative group (n = 5) was 16.6% (Table SI 1 ), and none of the patients in this group had vascular or lymphatic invasion (Table SII 1 ). On the other hand, the mean Ki-67 labelling index in the SLN metastasis- positive group (n = 3) was high (21.0%) (Table SI 1 ), and vascular and lymphatic invasion was observed in 2 of the 3 patients in this group (Table SIII 1 ). For all SLN metastasis-positive cases, postoperative chemotherapy was administered. The regimen for postoperative chemotherapy was cisplatin (60 mg/m 2 ) and doxoru- bicin (Adriamycin) (30 mg/m 2 ) once a month. The regimen was based on that used for advanced squamous cell carcinoma (SCC). However, continuation of this regimen is likely to cause bone mar- row suppression, kidney damage, and cardiotoxicity. Therefore, it can be administered for only 3 cycles. There were no serious side-effects, however. In case number 2 (Table SIII 1 ), the patient requested to be administered only one cycle. Table SIV 1 shows the clinicopathological features of the RLN dissection group. The mean observation period was 30.7 months. All patients in the RLN dissection group had lymphatic invasion. In addition, the mean Ki- 67 labelling index was as high as 32.3% (Table SI 1 ). Postoperative chemotherapy was administered to all 4 of the patients, but 2 of them died due to multiple distant metastasis. The primary regimen for postoperative chemotherapy was cisplatin and Adriamycin once a month. The dose is described above. For patients showing a poor treatment response, docetaxel (60 mg/m 2 ) was administered monthly, and if this proved ineffective, irinotecan (100 mg/m 2 ) was administered on days 1, 8 and 15, and then every 4–5 weeks. After surgery, the levels of tumour markers (CEA and CYFRA) were checked monthly and CT imaging examinations performed every 3 months in all patients with EPC. However, if elevation of a tumour marker was evident, imaging was carried out promptly. DISCUSSION The utility of SLN biopsy for staging of malignant mela- noma and breast cancer has been well established (5, 6). Re- cently, SLN biopsy has also been attempted for patients with non-malignant melanoma, such as SCC and extramammary Paget’s disease, in which the lym­phoid route is thought to be the predominant metastatic pathway. Lymphatic metastasis is also believed to be the main mode of metastasis in EPC. We believe that to improve the prognosis of patients with EPC, it is important to perform SLN biopsy for identification of lymph node metastasis at an early stage and to perform RLN dissection in positive cases. However, few case reports of EPC have documented the use of SLN biopsy. This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta Journal Compilation © 2019 Acta Dermato-Venereologica. doi: 10.2340/00015555-3173 Acta Derm Venereol 2019; 99: 691–692